Morepen Laboratories Ltd vs Parmax Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.91 as of 05 May 15:30 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Parmax Pharma Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Parmax Pharma Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The revenue of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The ebitda of Parmax Pharma Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The net profit of Parmax Pharma Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Parmax Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Parmax Pharma Ltd

Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
The Company then discontinued their business activities for few years due to various reasons.
Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.

FAQs for the comparison of Morepen Laboratories Ltd and Parmax Pharma Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Parmax Pharma Ltd?

Market cap of Morepen Laboratories Ltd is 2,296 Cr while Market cap of Parmax Pharma Ltd is 11 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Parmax Pharma Ltd?

The stock performance of Morepen Laboratories Ltd and Parmax Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Parmax Pharma Ltd?

As of May 5, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.91. On the other hand, Parmax Pharma Ltd stock price is INR ₹32.0.

How do dividend payouts of Morepen Laboratories Ltd and Parmax Pharma Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Parmax Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.